We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lupron Depot (leuprolide acetate for depot suspension)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lupron Depot (leuprolide acetate for depot suspension)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    TAP Holdings received clearance from the FDA to market Lupron Depot(R)-4 Month 30 mg (leuprolide acetate for depot suspension) for palliative treatment of advanced prostate cancer. Because of the drug's long-acting formulation, patients receive only one injection of Lupron Depot-4 Month 30 mg every 16 weeks to treat their condition.

    Clinical Results

    In clinical trials, the safety and efficacy of Lupron Depot-4 Month 30 mg were similar to the other Lupron Depot formulations.

    Side Effects

    The most common side effect reported with Lupron Depot-4 Month 30 mg was hot flashes. Serum testosterone levels may increase approximately 50 percent above baseline during the first week of treatment. Like other treatment options, it may also cause impotence. Symptoms may worsen over the first few weeks of treatment. Lupron Depot is contraindicated in patients who exhibit hypersensitivity to GnRH, GnRH agonist analogs or any excipients in the product. This formulation is not indicated for use in women.

    Mechanism of Action

    Lupron Depot is in a class of drugs known as gonadotropin releasing hormone (GnRH) analogs. It works by inhibiting the production of the hormone testosterone, which may play a significant role in the growth of prostate cancer. Decreasing the levels of testosterone in the body may also alleviate bone pain and some urinary problems that may be associated with metastatic prostate cancer.

    Additional Information

    Prostate cancer is now the second leading cause of cancer deaths in men. In 1997, the American Cancer Society estimated that 334,500 men were newly diagnosed with prostate cancer and that approximately 41,800 will die from the disease in 1997.

    A???????????????

    Approval Date: 1997-07-01
    Date Created: 1997-08-05 12:00:00
    Company Name: TAP Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing